VCN 01
Alternative Names: VCN-01Latest Information Update: 29 May 2024
At a glance
- Originator VCN Biosciences
- Developer AstraZeneca; Theriva Biologics; VCN Biosciences
- Class Antineoplastics; Eye disorder therapies; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Hyaluronidase stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma
- Phase I/II Pancreatic cancer; Retinoblastoma; Squamous cell cancer
- Phase I Brain cancer; Ovarian cancer
- No development reported Solid tumours
Most Recent Events
- 23 May 2024 VCN 01 receives Fast Track designation for Adenocarcinoma [IV,Infusion] (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA
- 23 Apr 2024 Efficacy and adverse events data from a phase I trial in Retinoblastoma released by Theriva Biologics
- 23 Apr 2024 Pharmacodynamics and safety data from preclinical studies in Pancreatic cancer released by Theriva Biologics